CCR5 and metabolic dysfunction-associated steatohepatitis: Regarding the CCR2/CCL2 and CCR5/CCL5 systems, an oral dual CCR2/CCR5 antagonist, cenicriviroc (CVC), has been developed and is currently being evaluated in NASH patients.